Looking for a 100% return? Explore these 2 AIM pharma stocks

Highlights

• Futura Medical collaborated with m8 Pharmaceuticals, OCT Clinical, and Labatec Pharma for the licensing and commercialisation of its MED3000 treatment.
• For the H1 ended 30 June 2021, Ergomed recorded revenue growth of 38.8% year-on-year to £56.0 million from £40.4 million in H1 2020.

The AIM-submarket of the London Stock Exchange (LSE) currently hosts a multitude of small-cap pharma companies that have been offering attractive returns to shareholders. The shares of these companies often receive a boost from new collaborations, inking of licensing and commercialisation agreements, and fresh fundraising rounds.

AIM stocks often belong to small-cap companies but have the capability to attract the attention of investors due to their high returns. Here we are discussing 2 AIM-listed healthcare stocks, Futura Medical and Ergomed that offered a return of 100% to shareholders in the last one year.

(Data source: Refinitiv)

Futura Medical Plc (LON: FUM)

Futura Medical is a British pharmaceutical firm engaged in the research and development of pharmaceutical drugs and medical devices for the consumer healthcare segment. Futura Medical inked a licensing agreement with m8 Pharmaceuticals to develop and commercialise its MED3000 treatment in Mexico and Brazil. It also partnered with OCT Clinical for conducting an FM71 clinical study for MED3000 in Poland, Bulgaria, the US, and Georgia. The company entered into a licensing contract with Labatec Pharma for the rights to commercialise MED3000 in GCC, Lebanon, Jordan, and Iraq.

Looking for a 100% return? Explore these 2 AIM pharma stocks

For H1 ended 30 June 2021, Futura Medical recorded a net loss of £1.59 million compared to a net loss of £1.06 million in H1 2020. In May 2021, it conducted fundraising of £12 million, including a retail offer.

The shares of Futura Medical closed at GBX 35.81, up by 1.27% on 10 November 2021. The market cap of the company stands at £101.48 million, and the shares of the company returned 132.02% to shareholders in the last one year.

Ergomed Plc (LON: ERGO)

Ergomed is a CRO offering Phase I–III clinical services and post-marketing pharmacovigilance (Phase IV) services. It is focused on orphan drugs, oncology, rare diseases, etc. Ergomed’s PrimeVigilance business established its new legal entity and a regional office in Japan on 26 April 2021.

For the H1 ended 30 June 2021, Ergomed recorded revenue growth of 38.8% year-on-year to £56.0 million compared to £40.4 million in H1 2020. Its order book as of 30 June 2021 was £227.8 million compared to £151.4 million in the previous year, representing an increase of 50.5% year-on-year.

The shares of Ergomed closed at GBX 1,520.00, up by 2.70% on 10 November 2021. The market cap of the company stands at £726.93 million, and the shares of the company returned 93.03% to shareholders in the last one year.